Reported Earnings • Aug 09
First quarter 2027 earnings released: EPS: ₹1.54 (vs ₹0.15 in 1Q 2026) First quarter 2027 results: EPS: ₹1.54 (up from ₹0.15 in 1Q 2026). Revenue: ₹174.1m (up 133% from 1Q 2026). Net income: ₹16.9m (up ₹15.3m from 1Q 2026). Profit margin: 9.7% (up from 2.3% in 1Q 2026). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 11% per year whereas the company’s share price has increased by 13% per year. Anuncio • Aug 03
Arvee Laboratories (India) Ltd. to Report Q1, 2027 Results on Aug 07, 2026 Arvee Laboratories (India) Ltd. announced that they will report Q1, 2027 results on Aug 07, 2026 Reported Earnings • May 21
Full year 2026 earnings released: EPS: ₹2.29 (vs ₹1.95 in FY 2025) Full year 2026 results: EPS: ₹2.29 (up from ₹1.95 in FY 2025). Revenue: ₹322.0m (down 16% from FY 2025). Net income: ₹25.3m (up 18% from FY 2025). Profit margin: 7.8% (up from 5.6% in FY 2025). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 19% per year but the company’s share price has increased by 14% per year, which means it is well ahead of earnings. Anuncio • May 05
Arvee Laboratories (India) Ltd. to Report Fiscal Year 2026 Results on May 18, 2026 Arvee Laboratories (India) Ltd. announced that they will report fiscal year 2026 results on May 18, 2026 Reported Earnings • Feb 17
Third quarter 2026 earnings released: EPS: ₹1.66 (vs ₹0.14 in 3Q 2025) Third quarter 2026 results: EPS: ₹1.66 (up from ₹0.14 in 3Q 2025). Revenue: ₹97.8m (up 9.8% from 3Q 2025). Net income: ₹18.3m (up ₹16.7m from 3Q 2025). Profit margin: 19% (up from 1.7% in 3Q 2025). The increase in margin was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 39% per year but the company’s share price has increased by 17% per year, which means it is well ahead of earnings. Anuncio • Feb 06
Arvee Laboratories (India) Ltd. to Report Q3, 2026 Results on Feb 13, 2026 Arvee Laboratories (India) Ltd. announced that they will report Q3, 2026 results on Feb 13, 2026 New Risk • Dec 05
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 13% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (7.8% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (1.5% net profit margin). Revenue is less than US$5m (₹263m revenue, or US$2.9m). Market cap is less than US$100m (₹2.18b market cap, or US$24.2m). New Risk • Nov 18
New minor risk - Profit margin trend The company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 1.5% Last year net profit margin: 6.2% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 13% per year over the past 5 years. Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (1.5% net profit margin). Revenue is less than US$5m (₹264m revenue, or US$3.0m). Market cap is less than US$100m (₹1.85b market cap, or US$20.8m). Board Change • Sep 23
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Additional Director Shalini Jalan was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Aug 15
First quarter 2026 earnings released: EPS: ₹0.15 (vs ₹0.85 in 1Q 2025) First quarter 2026 results: EPS: ₹0.15 (down from ₹0.85 in 1Q 2025). Revenue: ₹76.5m (down 28% from 1Q 2025). Net income: ₹1.69m (down 82% from 1Q 2025). Profit margin: 2.2% (down from 8.9% in 1Q 2025). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 37% per year but the company’s share price has increased by 26% per year, which means it is well ahead of earnings. Anuncio • Aug 13
Arvee Laboratories (India) Ltd., Annual General Meeting, Sep 24, 2025 Arvee Laboratories (India) Ltd., Annual General Meeting, Sep 24, 2025. New Risk • Jun 30
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 4.4% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (7.9% average weekly change). Revenue is less than US$5m (₹391m revenue, or US$4.6m). Market cap is less than US$100m (₹1.95b market cap, or US$22.8m). Valuation Update With 7 Day Price Move • Feb 25
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to ₹150, the stock trades at a trailing P/E ratio of 75.3x. Average trailing P/E is 25x in the Chemicals industry in India. Total returns to shareholders of 92% over the past three years. Reported Earnings • Feb 14
Third quarter 2025 earnings released: EPS: ₹0.14 (vs ₹0.22 in 3Q 2024) Third quarter 2025 results: EPS: ₹0.14 (down from ₹0.22 in 3Q 2024). Revenue: ₹89.1m (up 16% from 3Q 2024). Net income: ₹1.55m (down 35% from 3Q 2024). Profit margin: 1.7% (down from 3.1% in 3Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 21% per year but the company’s share price has increased by 19% per year, which means it is well ahead of earnings. New Risk • Dec 12
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.4% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.4% average weekly change). Earnings have declined by 2.5% per year over the past 5 years. High level of non-cash earnings (21% accrual ratio). Minor Risks Revenue is less than US$5m (₹370m revenue, or US$4.4m). Market cap is less than US$100m (₹2.49b market cap, or US$29.4m). Reported Earnings • Nov 16
Second quarter 2025 earnings released: EPS: ₹0.89 (vs ₹0.19 in 2Q 2024) Second quarter 2025 results: EPS: ₹0.89 (up from ₹0.19 in 2Q 2024). Revenue: ₹126.8m (up 42% from 2Q 2024). Net income: ₹9.81m (up 366% from 2Q 2024). Profit margin: 7.7% (up from 2.4% in 2Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 19% per year but the company’s share price has increased by 31% per year, which means it is well ahead of earnings. Reported Earnings • Aug 14
First quarter 2025 earnings released: EPS: ₹0.85 (vs ₹0.44 in 1Q 2024) First quarter 2025 results: EPS: ₹0.85 (up from ₹0.44 in 1Q 2024). Revenue: ₹107.1m (up 41% from 1Q 2024). Net income: ₹9.42m (up 93% from 1Q 2024). Profit margin: 8.8% (up from 6.4% in 1Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has increased by 25% per year, which means it is well ahead of earnings. Anuncio • Aug 13
Arvee Laboratories (India) Ltd., Annual General Meeting, Sep 28, 2024 Arvee Laboratories (India) Ltd., Annual General Meeting, Sep 28, 2024, at 11:30 Indian Standard Time. Anuncio • Mar 27
Arvee Laboratories (India) Ltd. Announces Resignation of Mr. Dipen Dalal as Independent Director Arvee Laboratories (India) Ltd. informed that Mr. Dipen Dalal, - Independent Director of the company has tendered his resignation vide letter dated March 26, 2024. He will be cease to be a Director of the company with effect from 26th March, 2024. Reported Earnings • Feb 14
Third quarter 2024 earnings released: EPS: ₹0.22 (vs ₹0.84 in 3Q 2023) Third quarter 2024 results: EPS: ₹0.22 (down from ₹0.84 in 3Q 2023). Revenue: ₹78.9m (down 52% from 3Q 2023). Net income: ₹2.38m (down 74% from 3Q 2023). Profit margin: 3.0% (down from 5.7% in 3Q 2023). The decrease in margin was driven by lower revenue. New Risk • Dec 06
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.2% average weekly change). Profit margins are more than 30% lower than last year (4.4% net profit margin). Revenue is less than US$5m (₹369m revenue, or US$4.4m). Market cap is less than US$100m (₹1.39b market cap, or US$16.7m). Reported Earnings • Nov 10
Second quarter 2024 earnings released: EPS: ₹0.19 (vs ₹1.86 in 2Q 2023) Second quarter 2024 results: EPS: ₹0.19 (down from ₹1.86 in 2Q 2023). Revenue: ₹90.0m (down 60% from 2Q 2023). Net income: ₹2.11m (down 90% from 2Q 2023). Profit margin: 2.3% (down from 9.0% in 2Q 2023). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has increased by 43% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • Aug 13
First quarter 2024 earnings released: EPS: ₹0.44 (vs ₹1.03 in 1Q 2023) First quarter 2024 results: EPS: ₹0.44 (down from ₹1.03 in 1Q 2023). Revenue: ₹76.9m (down 58% from 1Q 2023). Net income: ₹4.87m (down 57% from 1Q 2023). Profit margin: 6.3% (in line with 1Q 2023). Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has increased by 74% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • Jun 19
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to ₹124, the stock trades at a trailing P/E ratio of 33.1x. Average trailing P/E is 23x in the Chemicals industry in India. Total returns to shareholders of 519% over the past three years. Reported Earnings • May 08
Full year 2023 earnings released: EPS: ₹4.43 (vs ₹2.34 in FY 2022) Full year 2023 results: EPS: ₹4.43 (up from ₹2.34 in FY 2022). Revenue: ₹697.9m (up 73% from FY 2022). Net income: ₹41.2m (up 60% from FY 2022). Profit margin: 5.9% (down from 6.4% in FY 2022). The decrease in margin was driven by higher expenses. Valuation Update With 7 Day Price Move • Apr 26
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to ₹106, the stock trades at a trailing P/E ratio of 23.8x. Average trailing P/E is 21x in the Chemicals industry in India. Total loss to shareholders of 7.3% over the past year. Valuation Update With 7 Day Price Move • Apr 11
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₹108, the stock trades at a trailing P/E ratio of 24.3x. Average trailing P/E is 20x in the Chemicals industry in India. Total returns to shareholders of 359% over the past three years. Reported Earnings • Feb 05
Third quarter 2023 earnings released: EPS: ₹0.84 (vs ₹0.48 in 3Q 2022) Third quarter 2023 results: EPS: ₹0.84 (up from ₹0.48 in 3Q 2022). Revenue: ₹162.5m (up 106% from 3Q 2022). Net income: ₹9.21m (up 73% from 3Q 2022). Profit margin: 5.7% (down from 6.8% in 3Q 2022). The decrease in margin was driven by higher expenses. Valuation Update With 7 Day Price Move • Dec 20
Investor sentiment improved over the past week After last week's 28% share price gain to ₹160, the stock trades at a trailing P/E ratio of 39.1x. Average trailing P/E is 20x in the Chemicals industry in India. Total returns to shareholders of 97% over the past year. Valuation Update With 7 Day Price Move • Dec 05
Investor sentiment improved over the past week After last week's 20% share price gain to ₹115, the stock trades at a trailing P/E ratio of 28x. Average trailing P/E is 20x in the Chemicals industry in India. Total returns to shareholders of 44% over the past year. Reported Earnings • Nov 16
Second quarter 2023 earnings released: EPS: ₹1.86 (vs ₹0.66 in 2Q 2022) Second quarter 2023 results: EPS: ₹1.86 (up from ₹0.66 in 2Q 2022). Revenue: ₹228.0m (up 113% from 2Q 2022). Net income: ₹20.5m (up 182% from 2Q 2022). Profit margin: 9.0% (up from 6.8% in 2Q 2022). The increase in margin was driven by higher revenue. Reported Earnings • Nov 13
Second quarter 2023 earnings released: EPS: ₹1.86 (vs ₹0.66 in 2Q 2022) Second quarter 2023 results: EPS: ₹1.86 (up from ₹0.66 in 2Q 2022). Revenue: ₹228.0m (up 113% from 2Q 2022). Net income: ₹20.5m (up 182% from 2Q 2022). Profit margin: 9.0% (up from 6.8% in 2Q 2022). The increase in margin was driven by higher revenue. Valuation Update With 7 Day Price Move • Sep 19
Investor sentiment improved over the past week After last week's 20% share price gain to ₹101, the stock trades at a trailing P/E ratio of 34.9x. Average trailing P/E is 20x in the Chemicals industry in India. Total returns to shareholders of 14% over the past year. Reported Earnings • Aug 03
First quarter 2023 earnings released: EPS: ₹1.03 (vs ₹0.48 in 1Q 2022) First quarter 2023 results: EPS: ₹1.03 (up from ₹0.48 in 1Q 2022). Revenue: ₹182.0m (up 101% from 1Q 2022). Net income: ₹11.4m (up 116% from 1Q 2022). Profit margin: 6.3% (up from 5.8% in 1Q 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has increased by 48% per year, which means it is tracking significantly ahead of earnings growth. Anuncio • Jul 14
Arvee Laboratories (India) Ltd., Annual General Meeting, Aug 04, 2022 Arvee Laboratories (India) Ltd., Annual General Meeting, Aug 04, 2022, at 11:30 Indian Standard Time. Location: Registered Office of the Company situated at 403, Entice Nr. Jayantilal Park BRTS, Iskcon-Bopal Road Ahemdabad Gujarat India Agenda: To receive, consider and adopt the Audited Balance Sheet as at 31st March, 2022 and Statement of Profit and Loss and Cash Flow Statement for the year ended on 31st March, 2022 and the Reports of the Board of Directors and Auditors thereon and documents annexed thereto; to reappoint Mr. Shalin Bharatbhai Chokshi a Director of the Company who retires by rotation and being eligible offers himself for re-appointment; to appoint statutory auditor of the Company. Valuation Update With 7 Day Price Move • Jul 06
Investor sentiment improved over the past week After last week's 25% share price gain to ₹90.15, the stock trades at a trailing P/E ratio of 38.6x. Average trailing P/E is 17x in the Chemicals industry in India. Total returns to shareholders of 206% over the past three years. Valuation Update With 7 Day Price Move • Jun 22
Investor sentiment deteriorated over the past week After last week's 21% share price decline to ₹66.20, the stock trades at a trailing P/E ratio of 28.3x. Average trailing P/E is 17x in the Chemicals industry in India. Total returns to shareholders of 124% over the past three years. Reported Earnings • May 28
Full year 2022 earnings released: EPS: ₹2.34 (vs ₹2.43 in FY 2021) Full year 2022 results: EPS: ₹2.34 (down from ₹2.43 in FY 2021). Revenue: ₹407.9m (down 14% from FY 2021). Net income: ₹25.7m (down 3.9% from FY 2021). Profit margin: 6.3% (up from 5.7% in FY 2021). The increase in margin was driven by lower expenses. Valuation Update With 7 Day Price Move • May 06
Investor sentiment deteriorated over the past week After last week's 15% share price decline to ₹88.80, the stock trades at a trailing P/E ratio of 44x. Average trailing P/E is 20x in the Chemicals industry in India. Total loss to shareholders of 50% over the past year. Valuation Update With 7 Day Price Move • Mar 09
Investor sentiment improved over the past week After last week's 19% share price gain to ₹92.90, the stock trades at a trailing P/E ratio of 46.1x. Average trailing P/E is 17x in the Chemicals industry in India. Total returns to shareholders of 238% over the past three years. Reported Earnings • Feb 10
Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations Third quarter 2022 results: EPS: ₹0.48 (down from ₹1.39 in 3Q 2021). Revenue: ₹79.0m (down 60% from 3Q 2021). Net income: ₹5.34m (down 65% from 3Q 2021). Profit margin: 6.8% (down from 7.7% in 3Q 2021). The decrease in margin was driven by lower revenue. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has increased by 47% per year, which means it is well ahead of earnings. Valuation Update With 7 Day Price Move • Jan 24
Investor sentiment improved over the past week After last week's 16% share price gain to ₹98.35, the stock trades at a trailing P/E ratio of 33.7x. Average trailing P/E is 20x in the Chemicals industry in India. Valuation Update With 7 Day Price Move • Oct 27
Investor sentiment deteriorated over the past week After last week's 15% share price decline to ₹74.90, the stock trades at a trailing P/E ratio of 30.5x. Average trailing P/E is 18x in the Chemicals industry in India. Total returns to shareholders of 158% over the past three years. Executive Departure • Sep 23
Independent Director Paragbhai Shah has left the company On the 16th of September, Paragbhai Shah's tenure as Independent Director ended after 1.2 years in the role. We don't have any record of a personal shareholding under Paragbhai's name. Paragbhai is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 3.33 years. Valuation Update With 7 Day Price Move • Aug 16
Investor sentiment deteriorated over the past week After last week's 17% share price decline to ₹89.00, the stock trades at a trailing P/E ratio of 40.8x. Average trailing P/E is 20x in the Chemicals industry in India. Total returns to shareholders of 242% over the past three years. Reported Earnings • Jul 18
First quarter 2022 earnings released: EPS ₹0.48 (vs ₹0.91 in 1Q 2021) The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2022 results: Revenue: ₹91.2m (up 1.0% from 1Q 2021). Net income: ₹5.29m (up 5.2% from 1Q 2021). Profit margin: 5.8% (up from 5.6% in 1Q 2021). Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has increased by 62% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • Jun 20
Full year 2021 earnings released: EPS ₹2.43 (vs ₹2.02 in FY 2020) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: ₹479.6m (up 5.6% from FY 2020). Net income: ₹26.8m (up 20% from FY 2020). Profit margin: 5.6% (up from 4.9% in FY 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has increased by 64% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • Jun 14
Investor sentiment improved over the past week After last week's 28% share price gain to ₹122, the stock trades at a trailing P/E ratio of 60.2x. Average trailing P/E is 21x in the Chemicals industry in India. Total returns to shareholders of 359% over the past three years. Valuation Update With 7 Day Price Move • May 21
Investor sentiment deteriorated over the past week After last week's 23% share price decline to ₹159, the stock trades at a trailing P/E ratio of 78.8x. Average trailing P/E is 20x in the Chemicals industry in India. Total returns to shareholders of 469% over the past three years.